Literature DB >> 19424170

Prostate cancer: thalidomide for prostate cancer: is there progress?

Eleni Efstathiou, Christopher J Logothetis.   

Abstract

Upon its 'reinvention', thalidomide was quickly applied to 'microenvironment-dependent' diseases such as multiple myeloma, yet its role in the solid tumor spectrum has not been validated. A report into recurrent prostate cancer by Figg et al. shows that thalidomide can reduce time to PSA progression in patients treated with androgen deprivation therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19424170     DOI： 10.1038/nrurol.2009.68

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  7 in total

1.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

Authors:  W D Figg; W Dahut; P Duray; M Hamilton; A Tompkins; S M Steinberg; E Jones; A Premkumar; W M Linehan; M K Floeter; C C Chen; S Dixon; D R Kohler; E A Krüger; E Gubish; J M Pluda; E Reed
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

Review 2.  Drug insight: thalidomide as a treatment for multiple myeloma.

Authors:  Shaji Kumar; Kenneth C Anderson
Journal:  Nat Clin Pract Oncol       Date:  2005-05

3.  Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer.

Authors:  Eleni Efstathiou; Patricia Troncoso; Sijin Wen; Kim-Anh Do; Curtis A Pettaway; Louis L Pisters; Timothy J McDonnell; Christopher J Logothetis
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

4.  Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies.

Authors:  Shifeng Mao; Danai D Daliani; Xuemei Wang; Peter F Thall; Kim-Anh Do; Cherie A Perez; Melissa A Brown; Kathleen Bouchillon; Cindy M Carter; Christopher J Logothetis; Jeri Kim
Journal:  Prostate       Date:  2007-11-01       Impact factor: 4.104

5.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.

Authors:  William L Dahut; James L Gulley; Philip M Arlen; Yinong Liu; Katherine M Fedenko; Seth M Steinberg; John J Wright; Howard Parnes; Clara C Chen; Elizabeth Jones; Catherine E Parker; W Marston Linehan; William D Figg
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

6.  Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.

Authors:  Jorge A Garcia; Eric A Klein; Cristina Magi-Galluzzi; Paul Elson; Pierre Triozzi; Robert Dreicer
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

7.  A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

Authors:  William D Figg; Maha H Hussain; James L Gulley; Philip M Arlen; Jeanny B Aragon-Ching; Daniel P Petrylak; Celestia S Higano; Seth M Steinberg; Gurkamal S Chatta; Howard Parnes; John J Wright; Oliver Sartor; William L Dahut
Journal:  J Urol       Date:  2009-01-23       Impact factor: 7.450
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.